What is Ceralasertib used for?

Ceralasertib, also known by its research code AZD6738, is a promising drug currently under investigation in the field of oncology. As a small-molecule inhibitor, Ceralasertib specifically targets ataxia telangiectasia and Rad3-related protein (ATR), a key player in the DNA damage response (DDR) pathway. Research into this compound has been driven by institutions such as AstraZeneca, a global, science-led biopharmaceutical company. Ceralasertib is primarily categorized as a targeted cancer therapy, with indications for various types of cancer, including solid tumors like non-small cell lung cancer (NSCLC) and ovarian cancer. The research progress for Ceralasertib is still ongoing, with multiple clinical trials in different phases aimed at evaluating its efficacy and safety both as a monotherapy and in combination with other treatments.

The mechanism of action for Ceralasertib revolves around its inhibition of the ATR protein. ATR plays a critical role in the cellular response to DNA damage, which is a fundamental aspect of cancer cell survival and proliferation. When DNA damage occurs, ATR is activated to initiate a cascade of events that halt the cell cycle, allowing time for the cell to repair its damaged DNA. By inhibiting ATR, Ceralasertib essentially cripples the cancer cell's ability to repair its DNA, leading to an accumulation of DNA damage. This accumulation ultimately triggers cell death, particularly in cancer cells that are heavily reliant on ATR due to their high rates of replication and inherent genetic instability.

 

Researching Ceralasertib beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Ceralasertib with Hiro LS Researcher →

ATR inhibition is a strategic and targeted approach in cancer therapy, particularly effective against tumors with defects in other components of the DDR pathway, such as the ATM (ataxia-telangiectasia mutated) protein or the BRCA1/2 genes. These defects are often present in various cancers, making Ceralasertib a potentially broad-spectrum anticancer agent.

One of the primary indications for Ceralasertib is its use in treating solid tumors, including but not limited to non-small cell lung cancer (NSCLC) and ovarian cancer. NSCLC is one of the most common types of lung cancer, accounting for approximately 85% of all lung cancer cases. Traditional treatments for NSCLC include surgery, chemotherapy, and radiotherapy, but these methods often fall short due to the aggressive nature of the disease and the development of resistance. Ceralasertib offers a novel mechanism that specifically targets the cancer cells' ability to repair themselves, presenting a new avenue for treatment.

Similarly, ovarian cancer, known for its poor prognosis and high recurrence rate, has been a focus of research for Ceralasertib. As with NSCLC, the reliance of ovarian cancer cells on the DDR pathway makes ATR inhibition a promising therapeutic strategy. In ongoing clinical trials, Ceralasertib has been evaluated both as a standalone treatment and in combination with other drugs such as olaparib, a PARP inhibitor. The combination therapy aims to exploit synthetic lethality, a scenario where the simultaneous impairment of two genes leads to cell death, while the impairment of just one does not. By combining ATR and PARP inhibition, researchers hope to achieve a more effective eradication of cancer cells.

In addition to NSCLC and ovarian cancer, other potential indications for Ceralasertib include various forms of solid tumors and hematological malignancies. The drug's ability to disrupt the DDR pathway provides a versatile tool in the fight against cancer, making it applicable across a wide range of cancer types that share this common vulnerability.

Ceralasertib represents a significant advancement in targeted cancer therapy, offering hope for more effective treatment options for patients with difficult-to-treat cancers. Its mechanism of action, centered on ATR inhibition, provides a novel approach that complements existing treatment modalities. The ongoing research and clinical trials will be crucial in determining the full potential of Ceralasertib, but the preliminary results are promising, opening new horizons in the realm of oncology. As the scientific community continues to unravel the complexities of cancer biology, drugs like Ceralasertib are at the forefront of a new era of personalized and precision medicine.

Continue your Ceralasertib research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What approved and investigational uses have been reported for Ceralasertib?
• What is the mechanism of action of Ceralasertib, and which targets or pathways are involved?
• Which clinical trials are evaluating Ceralasertib, and what outcomes have been reported?
• What patents, publications, and regulatory sources provide the latest evidence on Ceralasertib?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.